Shamseddine, Ali
Zeidan, Youssef H.
El Husseini, Ziad
Kreidieh, Malek
Al Darazi, Monita
Turfa, Rim
Kattan, Joseph
Khalifeh, Ibrahim
Mukherji, Deborah
Temraz, Sally
Alqasem, Kholoud
Amarin, Rula
Al Awabdeh, Tala
Deeba, Samer
Jamali, Faek
Mohamad, Issa
Elkhaldi, Mousa
Daoud, Faiez
Al Masri, Mahmoud
Dabous, Ali
Hushki, Ahmad
Jaber, Omar
Charafeddine, Maya
Geara, Fady
Funding for this research was provided by:
Merck KGaA
Article History
Received: 28 April 2020
Accepted: 24 September 2020
First Online: 7 October 2020
Ethics approval and consent to participate
: The study protocol (IRB Number: BIO-2017-0422) was approved by the appropriate independent ethics committee (IEC) corresponding to each of the three centers, including the Institutional Review Board at AUBMC for instance. This clinical study is carried out in accordance with the globally accepted standards of GCP and in compliance with applicable regulatory authority requirements<i>.</i> Prior to enrollment in the trial, written informed consent must be obtained from each participant. Not only should the investigator provide relevant, comprehensive, verbal, and written information regarding the objectives and procedures of the study, but also s/he must list the possible risks involved. The patient should have enough time to inquire about study details, and all his/her questions should be answered in a clear and timely manner. His/her right to withdraw from the study at any time must be made clear. Two original copies of the informed consent form should be signed and dated by the patient, or a designated person, and by the Investigator.
: Not applicable.
: The authors have no competing interests to declare.